Substantial heterogeneity in the performance of open-source VLMs in brain metastasis evaluation is demonstrated, and medical-purpose VLMs did not outperform general-purpose VLMs.
Abstract
Purpose Open-source vision-language models (VLMs) can be locally deployed without external internet access, potentially enhancing data security. This study compared the diagnostic performance of general-purpose and medical-purpose open-source VLMs and evaluated their ability to characterize brain metastases on contrast-enhanced (CE) MRI. Materials and Methods Sixty lesion-positive axial CE T1-weighted images and sixty matched lesion-negative images from 60 patients were analyzed using three general-purpose VLMs-InternVL3-8B, Qwen2.5-VL-7B-Instruct, and MiniCPM-V-4.5-and three medical-purpose VLMs-MedGemma-4B-it, LLaVA-Med v1.5, and HuatuoGPT-Vision-7B. Lesion detection performance was assessed using sensitivity, specificity, and balanced accuracy. On lesion-positive images, accuracy was evaluated for lesion count, laterality, anatomic location, enhancement pattern, necrosis, vasogenic edema, and mass effect. Model differences were assessed using Cochran's Q tests followed by pairwise McNemar tests with Benjamini-Hochberg correction. Results The median age of the study patients was 67 years (IQR, 61.0-70.5 years), and 35 patients were male (58.3%). MiniCPM-V-4.5 showed the most balanced diagnostic performance, with a sensitivity of 78.3% (95% CI, 66.4-86.9%) and a specificity of 85.0% (95% CI, 73.9-91.9%), and significantly higher balanced accuracy than all other models. Significant overall differences were observed for lesion count, laterality, location, enhancement pattern, necrosis, and mass effect, but not for vasogenic edema (FDR-adjusted P = 0.056). HuatuoGPT-Vision-7B and MedGemma-4B-it showed relatively consistent accuracy across multiple image assessment tasks, although their performance remained modest. Conclusion Our study demonstrated substantial heterogeneity in the performance of open-source VLMs in brain metastasis evaluation, and medical-purpose VLMs did not outperform general-purpose VLMs.
An explainable transfer-learning framework for four-class brain tumor classification (glioma, meningioma, pituitary tumor, and no-tumor) in which MobileNetV2, ResNet50, and EfficientNetB0 are compared under a common training protocol is presented.
Sif K. Ebis· Journal of Al-Farabi for Eng...· 0 citations
Adding the evaluated RAG configuration did not improve diagnostic accuracy and was associated with text-related diagnostic errors under smartphone-captured degraded imaging conditions, suggesting that persona design may influence the robustness of VLM responses to retrieved information, but this observation requires va...
RATIONALE AND OBJECTIVES
To develop and validate a brain imaging-based multimodal radiomics model for noninvasive prediction of pathological subtypes in lung cancer patients with brain metastases, and to evaluate the effects of imaging modalities, computed tomography, contrast-enhanced T1-weighted imaging, T2-weighted ...
Jia-Shi Geng, Jian-Yu Xu, Hong-Kai Liu et al.· Academic Radiology· 0 citations
Publicly available multimodal LLMs showed measurable but heterogeneous performance in grayscale ultrasound-based thyroid nodule classification, but none of the models matched senior radiologist-level performance.
DL applied to liver MRI yielded promising model-derived patient-level summaries, but four retrospective, geographically concentrated cohorts do not establish a transportable accuracy benchmark, radiologist augmentation, or clinical benefit.
B. T. Mengistie, K. Y. Gete, Amira G. Mohammed et al.· Egyptian Liver Journal· 0 citations
In this multi-center, multi-reader study, deep learning-based contrast boosting demonstrates robust improvements in lesion visualization and image quality without increasing contrast dosage.
Srivathsa Pasumarthi Venkata, T. Arnold, Sonia Colombo Serra et al.· Journal of Magnetic Resonanc...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.